Literature DB >> 18695884

Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer.

M Svoboda1, L Izakovicova Holla, R Sefr, I Vrtkova, I Kocakova, B Tichy, J Dvorak.   

Abstract

There is increasing evidence that some microRNAs change their levels in reaction to xenobiotic challenge. The aim of this study was to test the possible involvement of micro-RNAs in response to standard anticancer treatment. Tumor biopsies from 35 patients with rectal cancer before therapy and parallel tumor biopsies from 31 patients two weeks after starting preoperative capecitabine chemoradiotherapy were taken. The expression levels of single miRNA species were measured using TaqMan Micro-RNA assays after reverse transcription from isolated total RNAs. Many micro-RNAs (miR10a, miR21, miR145, miR212, miR339, miR361) responded to chemoradiotherapy in individual tumor samples, but there was profound intertumoral variability. However, other two micro-RNAs miR125b, miR137 showed a significant increase in median expression levels after starting therapy in most samples. Moreover, our results for the first time show that higher induced levels of miR125b and miR137 are associated with worse response to the therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695884

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  51 in total

1.  Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients.

Authors:  Moubin Lin; Jian Gu; Cathy Eng; Lee M Ellis; Michelle A Hildebrandt; Jie Lin; Maosheng Huang; George A Calin; Dingzhi Wang; Raymond N Dubois; Ernest T Hawk; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2012-06-01       Impact factor: 12.531

2.  Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? Proposing a new hypothesis [corrected].

Authors:  Chiranjib Chakraborty; C George Priya Doss; Renu Sarin; Minna J Hsu; Govindasamy Agoramoorthy
Journal:  Protoplasma       Date:  2015-02-20       Impact factor: 3.356

3.  Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival.

Authors:  K R Delfino; N V L Serão; B R Southey; S L Rodriguez-Zas
Journal:  Cancer Genomics Proteomics       Date:  2011 Jul-Aug       Impact factor: 4.069

Review 4.  Role of 3'-untranslated region translational control in cancer development, diagnostics and treatment.

Authors:  Andrii Vislovukh; Thaiz Rivera Vargas; Anna Polesskaya; Irina Groisman
Journal:  World J Biol Chem       Date:  2014-02-26

5.  High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer.

Authors:  Dong Won Baek; Gyeonghwa Kim; Byung Woog Kang; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu-Seog Choi; Min Kyu Kang; Keun Hur; Jong Gwang Kim
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-28       Impact factor: 4.553

Review 6.  Serum miRNAs as Biomarkers for the Diagnosis and Prognosis of Thyroid Cancer: A Comprehensive Review of the Literature.

Authors:  Mohammad-Reza Mahmoudian-Sani; Ameneh Mehri-Ghahfarrokhi; Majid Asadi-Samani; Gholam-Reza Mobini
Journal:  Eur Thyroid J       Date:  2017-04-07

Review 7.  MicroRNA in rectal cancer.

Authors:  Azadeh Azizian; Jens Gruber; B Michael Ghadimi; Jochen Gaedcke
Journal:  World J Gastrointest Oncol       Date:  2016-05-15

8.  MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer.

Authors:  Kah Hoong Chang; Pieter Mestdagh; Jo Vandesompele; Michael J Kerin; Nicola Miller
Journal:  BMC Cancer       Date:  2010-04-29       Impact factor: 4.430

Review 9.  Epigenetics of colorectal cancer.

Authors:  Ajay Goel; C Richard Boland
Journal:  Gastroenterology       Date:  2012-09-20       Impact factor: 22.682

Review 10.  MicroRNAs in colorectal cancer: translation of molecular biology into clinical application.

Authors:  Ondrej Slaby; Marek Svoboda; Jaroslav Michalek; Rostislav Vyzula
Journal:  Mol Cancer       Date:  2009-11-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.